Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Seq84
    Member
    • Feb 2011
    • 19

    Duplicates percentage in target resequencing

    Hi,

    We are performing a target resequencing experiment, where we enriched 8 regions.
    1. What's the mean % of duplicates in this kind of experiments ?
    2. The % in duplicates is casual or is affected by specifics factors?
    3. During quality control analysis we noticed that % in duplicates range from 1 to 80%, is it normal have high % of duplicates in a target resequencing experiment?
  • Heisman
    Senior Member
    • Dec 2010
    • 534

    #2
    A high duplicate percentage comes from (generally) too many PCR cycles pre-hybridization. For standard exomes we typically see < 5% PCR duplicates using Agilent SureSelect.

    Comment

    • NGSfan
      Senior Member
      • Apr 2009
      • 181

      #3
      Originally posted by Heisman View Post
      A high duplicate percentage comes from (generally) too many PCR cycles pre-hybridization. For standard exomes we typically see < 5% PCR duplicates using Agilent SureSelect.

      5% is impressively low. Would the target size range have an affect? We are sampling just 500 genes and not a whole exome. I've noticed PCR duplicates from 14% to 50% in our data. I am trying to convince the wet lab people to lower their PCR cycles.

      How many cycles are you doing? I think wetlab is doing 16 cycles..

      Comment

      • Heisman
        Senior Member
        • Dec 2010
        • 534

        #4
        If we can start with 3ug DNA we can get away with 7 or fewer PCR cycles. The protocol states to do 4-6 but when I've done 8 cycles I haven't had any issues. 16 prior to hybridization seems quite high, though. I communicated with an Agilent rep who told me that duplicates are mainly caused by too many cycles pre-hyb.

        Comment

        • Robby
          Member
          • Mar 2011
          • 68

          #5
          Hi,
          I think the number of reads and the target region size is important as well.

          But nevertheless we have the duplication problem as well. We used the Agilent AllExon-Kit and sequenced with the HiSeq (one lane per sample). We observed a duplication rate of 40-50%, although we sticked to the protocol. We observe, that the duplication rate with the GA II is much lower than with the HiSeq. Does anyone observe the same?

          How many reads did you map to which region size and which duplication rate did you observe?

          @Heisman: Did you sequence with the HiSeq or the GA II? How many reads did you receive?

          Comment

          • Heisman
            Senior Member
            • Dec 2010
            • 534

            #6
            @Robby: We sequence with the HiSeq and I get generally ~90-100 million reads. We map to the whole genome using novoalign but that shouldn't be a determining factor regarding how many duplicate reads there are. I have no idea why you are getting so many duplicates or, even more interestingly, why you would get less duplicates with the GAIIx. I've generally started with 3-4 ug DNA and done 7-8 PCR cycles pre-hybridization (around 12 after hybridization).

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM
            • SEQadmin2
              Cancer Drug Resistance: The Lingering Barrier to Rising Survival
              by SEQadmin2



              Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

              There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
              07-08-2026, 05:17 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            25 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            20 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-20-2026, 11:10 AM
            0 responses
            28 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-13-2026, 10:26 AM
            0 responses
            38 views
            0 reactions
            Last Post SEQadmin2  
            Working...